Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Revenue and Product Sales Performance
INCY logo

Incyte Revenues Surge 21% to $1.27 Billion Driven by JAKAFI and OPZELURA Growth

INCY10-QFiling Date: 4/28/2026
Incyte Corporation
Description

What this story covers

Incyte Corporation reported a 21% revenue increase to $1.27 billion, supported by a $4 billion cash reserve. While flagship drug JAKAFI remains strong, the company faces upcoming 2028 patent expirations and ongoing legal challenges regarding generic competition.

Story snapshot

CompanyIncyte Corporation
TickerINCY
VariantStandard detailed
Duration12:28
Filing type10-Q
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0000879169-26-000026
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-QView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in